Imricor Medical Systems Shares Surge 25% Following AI Partnership with ADIS

2 min read | November 28, 2024 04:12 PM AEDT | By Team Kalkine Media

Highlights

  • Groundbreaking Partnership: Imricor signs key licensing agreement with Swiss software firm ADIS to develop AI modules for its NorthStar 3D mapping system.
  • Stock Surge: Shares rise 25% to a 52-week high of $1.34, driven by investor excitement.
  • Future Impact: AI modules set to enhance MRI imaging efficiency, with a 2025 launch planned in Europe, US, and the Middle East.

Imricor Medical Systems Inc (ASX:IMR) saw its share price soar by 25%, reaching a 52-week high of AU$1.34 on Thursday, following the announcement of a transformative licensing agreement with the Swiss software company ADIS. The deal centers around the development of artificial intelligence (AI) modules that will integrate with Imricor’s cutting-edge NorthStar 3D mapping system, a breakthrough in medical imaging technology.

AI-Driven Innovation in MRI Imaging

The NorthStar system revolutionizes magnetic resonance imaging (MRI) by providing real-time image display, 3D mapping of electroanatomical data, and enhanced control over MRI scanners. The addition of AI modules, including automatic heart segmentation, will dramatically cut procedure times, reducing a 20-minute task to mere seconds, thereby improving both efficiency and accuracy for physicians.

Although these AI-enhanced modules are not yet commercially available, regulatory processes are progressing smoothly, with a projected 2025 launch across Europe, the US, and the Middle East. This advancement is poised to redefine the landscape of cardiac imaging, with Imricor positioning NorthStar as a critical tool in global MRI programs.

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.